Steering Sustainable Progress

We don’t just manufacture—we create meaningful impact

From R&D to last-mile delivery, sustainability is in every dose we deliver

...
ESG Embedded in Innovation

At MSN, innovation is not just about developing advanced medicines, it’s about doing so responsibly. We integrate environmental, social, and governance (ESG) considerations across the entire product life cycle, from discovery to distribution. Product Life Cycle Assessments (LCAs) guide our decisions on design, process efficiency, and impact reduction. We're also transitioning to green packaging and recyclable materials, while ensuring impeccable regulatory compliance with zero adverse regulatory audit records in over 20 years. This is innovation with integrity, engineered for people and the planet.

Highlights
  • Conducted Product Life Cycle Assessments (LCA) for key product categories
  • Use of eco-friendly and recyclable packaging materials
  • Zero adverse regulatory audit findings in the past 20 years
  • Focus on energy-efficient, sustainable manufacturing processes
Sustainable Supply Chain

At MSN, we engage with suppliers through a Sustainable Supplier Code of Conduct, aligning them with our environmental and ethical values. By mapping our Scope 3 emissions and implementing reduction strategies, we are advancing transparency and accountability throughout the supply chain. Our practices follow the globally recognized ISO 20400 standard for sustainable procurement, ensuring that every partnership we build contributes to long-term impact.

Highlights
  • Implementation of Sustainable Supplier Code of Conduct
  • Scope 3 emissions inventorying and reduction plans underway
  • Procurement practices aligned with ISO 20400 principles
  • Supplier assessments and sustainability onboarding initiatives
...
...
Patient Safety and Product Reach

At the heart of everything we do is the patient. We believe access to safe, effective, and affordable healthcare is a fundamental right. Our pharmacovigilance systems have been enhanced to ensure post-market safety through active Adverse Drug Reaction (ADR) monitoring. Through our vast distribution reach and targeted outreach to underserved regions, MSN impacted the lives of over 40 million patients in FY23–24 alone. Our commitment goes beyond products it’s about delivering care with consistency, safety, and compassion.

Highlights
  • Strengthened ADR monitoring and patient safety systems
  • Focused outreach to underserved and rural communities
  • 40+ million patients reached globally in FY23–24
  • Reliable, quality-assured access to essential medicines